

# Thomas R Kosten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7901677/publications.pdf>

Version: 2024-02-01

126  
papers

4,926  
citations

101543

36  
h-index

114465

63  
g-index

173  
all docs

173  
docs citations

173  
times ranked

5500  
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. <i>Molecular Psychiatry</i> , 2023, 28, 423-433.	7.9	107
2	Current status of vaccines for substance use disorders: A brief review of human studies. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120098.	0.6	18
3	Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 115, 110506.	4.8	2
4	A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality. <i>Chronic Stress</i> , 2022, 6, 247054702210837.	3.4	1
5	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 965-973.	1.9	1
6	Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial. <i>Neurotherapeutics</i> , 2022, 19, 1037-1046.	4.4	1
7	A systematic review and meta-analysis on prevalence of and risk factors associated with depression, anxiety and insomnia in infectious diseases, including COVID-19: a call to action. <i>Molecular Psychiatry</i> , 2022, 27, 3214-3222.	7.9	81
8	Current status of immunotherapies for addiction. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 3-16.	3.8	17
9	Genome-Wide Association Studies of Schizophrenia and Bipolar Disorder in a Diverse Cohort of US Veterans. <i>Schizophrenia Bulletin</i> , 2021, 47, 517-529.	4.3	48
10	Cingulate Cortex Structural Alterations in Substance Use Disorder Psychiatric Inpatients. <i>American Journal on Addictions</i> , 2021, 30, 72-79.	1.4	4
11	Cognitive Deficits and Clinical Symptoms with Hippocampal Subfields in First-Episode and Never-Treated Patients with Schizophrenia. <i>Cerebral Cortex</i> , 2021, 31, 89-96.	2.9	12
12	Internet Addiction Increases in the General Population During COVID-19: Evidence From China. <i>American Journal on Addictions</i> , 2021, 30, 389-397.	1.4	98
13	Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1682-1690.	2.6	21
14	A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers. <i>Scientific Reports</i> , 2021, 11, 9876.	3.3	5
15	Association of Symptoms of Attention Deficit and Hyperactivity with Problematic Internet Use among University Students in Wuhan, China During the COVID-19 Pandemic. <i>Journal of Affective Disorders</i> , 2021, 286, 220-227.	4.1	21
16	Fentanyl conjugate vaccine by injected or mucosal delivery with dmlT or LTA1 adjuvants implicates IgA in protection from drug challenge. <i>Npj Vaccines</i> , 2021, 6, 69.	6.0	19
17	The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. <i>Psychiatric Genetics</i> , 2021, 31, 88-94.	1.1	4
18	The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic. <i>JAMA Psychiatry</i> , 2021, 78, 585.	11.0	24

#	ARTICLE	IF	CITATIONS
19	Long-Term Impact of COVID-19 on Mental Health among the General Public: A Nationwide Longitudinal Study in China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8790.	2.6	37
20	Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. <i>Translational Psychiatry</i> , 2021, 11, 499.	4.8	35
21	Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. <i>EClinicalMedicine</i> , 2021, 40, 101111.	7.1	84
22	COVID-19 Vaccine-Related Psychological Stress Among General Public in China. <i>Frontiers in Psychiatry</i> , 2021, 12, 774504.	2.6	27
23	The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 264, 123-129.	4.1	50
24	Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. <i>Addictive Behaviors</i> , 2020, 111, 106538.	3.0	2
25	Mental health services for infectious disease outbreaks including COVID-19: a rapid systematic review. <i>Psychological Medicine</i> , 2020, 50, 2498-2513.	4.5	44
26	One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. <i>Neuropsychopharmacology</i> , 2020, 45, 1362-1368.	5.4	12
27	Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus. <i>Translational Psychiatry</i> , 2020, 10, 130.	4.8	19
28	Process genes list: An approach to link genetics and human brain imaging. <i>Journal of Neuroscience Methods</i> , 2020, 339, 108695.	2.5	5
29	Brief Report: Increased Addictive Internet and Substance Use Behavior During the COVID-19 Pandemic in China. <i>American Journal on Addictions</i> , 2020, 29, 268-270.	1.4	334
30	Altered habenula resting state functional connectivity in deprived veteran tobacco smokers: A pilot study. <i>Bulletin of the Menninger Clinic</i> , 2020, 84, 21-34.	0.6	2
31	Editorial: Challenges to Opioid Use Disorders During COVID-19. <i>American Journal on Addictions</i> , 2020, 29, 174-175.	1.4	68
32	Orbitofrontal, dorsal striatum, and habenula functional connectivity in psychiatric patients with substance use problems. <i>Addictive Behaviors</i> , 2020, 108, 106457.	3.0	14
33	Evolution of the Journal of the American Academy of Addiction Psychiatry: The American Journal on Addictions. <i>American Journal on Addictions</i> , 2020, 29, 375-377.	1.4	0
34	Keeping Up with Clinical Advances: Opioid Use Disorder. <i>CNS Spectrums</i> , 2019, 24, 14-24.	1.2	161
35	Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. <i>American Journal on Addictions</i> , 2019, 28, 480-488.	1.4	6
36	The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. <i>Schizophrenia Research</i> , 2019, 212, 92-98.	2.0	57

#	ARTICLE	IF	CITATIONS
37	Buprenorphine for the treatment of posttraumatic stress disorder. <i>American Journal on Addictions</i> , 2019, 28, 86-91.	1.4	13
38	Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. <i>American Journal on Addictions</i> , 2019, 28, 55-62.	1.4	131
39	Preclinical efficacy of an anti- $\epsilon$ -methamphetamine vaccine using E6020 adjuvant. <i>American Journal on Addictions</i> , 2019, 28, 119-126.	1.4	16
40	Pharmacogenetic Role of <i>Dopamine Transporter</i> ( <i>SLC6A3</i> ) Variation on Response to Disulfiram Treatment for Cocaine Addiction. <i>American Journal on Addictions</i> , 2019, 28, 311-317.	1.4	16
41	Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users. <i>Journal of Studies on Alcohol and Drugs</i> , 2019, 80, 230-235.	1.0	3
42	Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 78-88.	2.8	7
43	Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists. <i>Psychopharmacology</i> , 2019, 236, 2899-2907.	3.1	6
44	Insular resting state functional connectivity is associated with gut microbiota diversity. <i>European Journal of Neuroscience</i> , 2019, 50, 2446-2452.	2.6	35
45	Pharmacogenetics of <i>Dopamine <math>\beta</math>-Hydroxylase</i> in cocaine dependence therapy with doxazosin. <i>Addiction Biology</i> , 2019, 24, 531-538.	2.6	14
46	Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 69-76.	4.8	46
47	Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury. <i>JAMA Psychiatry</i> , 2018, 75, 642.	11.0	3
48	Exenatide once weekly for smoking cessation. <i>Medicine (United States)</i> , 2018, 97, e9567.	1.0	9
49	Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury. <i>JAMA Psychiatry</i> , 2018, 75, 649.	11.0	4
50	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , 2018, 187, 171-178.	3.2	35
51	Editorial. <i>American Journal on Addictions</i> , 2018, 27, 5-6.	1.4	0
52	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , 2018, 27, 177-187.	1.4	38
53	Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 66-76.	1.8	10
54	Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder. <i>Psychiatry Research - Neuroimaging</i> , 2018, 271, 59-66.	1.8	17

#	ARTICLE	IF	CITATIONS
55	A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. <i>Frontiers in Pharmacology</i> , 2018, 9, 712.	3.5	1
56	FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration. <i>American Journal on Addictions</i> , 2018, 27, 567-573.	1.4	10
57	Psychosis and synthetic cannabinoids. <i>Psychiatry Research</i> , 2018, 268, 400-412.	3.3	48
58	Psychopathology and personality traits associated with driving while intoxicated in Beijing, China: Implications for interventions. <i>American Journal on Addictions</i> , 2017, 26, 374-378.	1.4	2
59	Increased habenular connectivity in opioid users is associated with an $\hat{\pm}5$ subunit nicotinic receptor genetic variant. <i>American Journal on Addictions</i> , 2017, 26, 751-759.	1.4	24
60	Current status and future prospects for the development of substance abuse vaccines. <i>Expert Review of Vaccines</i> , 2017, 16, 1067-1077.	4.4	31
61	Smoking reduction and quality of life in chronic patients with schizophrenia in a Chinese population-A pilot study. <i>American Journal on Addictions</i> , 2016, 25, 86-90.	1.4	2
62	“Just one bad high”: Considering synthetic cannabinoid outcome expectancies in adolescents. <i>American Journal on Addictions</i> , 2016, 25, 620-622.	1.4	0
63	Smoking and Serum Lipid Profiles in Schizophrenia. <i>Neuroscience Bulletin</i> , 2016, 32, 383-388.	2.9	28
64	Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw029.	2.1	12
65	An Opioid for Depression?. <i>American Journal of Psychiatry</i> , 2016, 173, 446-447.	7.2	9
66	Update on pharmacotherapy for treatment of opioid use disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2307-2318.	1.8	60
67	Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naïve schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 116-124.	4.1	36
68	Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population. <i>Psychoneuroendocrinology</i> , 2016, 68, 140-147.	2.7	12
69	Interaction of BDNF with cytokines in chronic schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2016, 51, 169-175.	4.1	62
70	<i>ZNF804A</i> variants confer risk for heroin addiction and affect decision making and gray matter volume in heroin abusers. <i>Addiction Biology</i> , 2016, 21, 657-666.	2.6	21
71	Reinforcement sensitivity underlying treatment-seeking smokers’ affect, smoking reinforcement motives, and affective responses.. <i>Psychology of Addictive Behaviors</i> , 2015, 29, 300-311.	2.1	8
72	General Approaches to Substance Use Disorders. , 2015, , 1394-1400.		0

#	ARTICLE	IF	CITATIONS
73	Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine. <i>American Journal on Addictions</i> , 2015, 24, 748-755.	1.4	25
74	Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. <i>Drug and Alcohol Dependence</i> , 2015, 153, 306-313.	3.2	28
75	Withdrawal Symptoms and Nicotine Dependence Severity Predict Virtual Reality Craving in Cigarette-Deprived Smokers. <i>Nicotine and Tobacco Research</i> , 2015, 17, 796-802.	2.6	33
76	Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. <i>Psychiatry Research</i> , 2015, 230, 44-49.	3.3	10
77	A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic. <i>Neuropsychopharmacology</i> , 2015, 40, 2059-2065.	5.4	42
78	Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. <i>NeuroImage: Clinical</i> , 2015, 7, 837-847.	2.7	37
79	Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids. <i>Journal of Drug Abuse</i> , 2015, 1, 1-6.	0.2	3
80	Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China. <i>American Journal on Addictions</i> , 2014, 23, 313-317.	1.4	11
81	Vaccines against stimulants: cocaine and MAO-A. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 368-374.	2.4	56
82	Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. <i>Drug and Alcohol Dependence</i> , 2014, 140, 42-47.	3.2	129
83	Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1370-1375.	3.1	29
84	Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine $\beta$ -Hydroxylase. <i>Biological Psychiatry</i> , 2013, 73, 219-224.	1.3	99
85	Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls. <i>Brain, Behavior, and Immunity</i> , 2013, 32, 105-111.	4.1	42
86	Pharmacotherapy for Stimulant-Related Disorders. <i>Current Psychiatry Reports</i> , 2013, 15, 415.	4.5	14
87	DBH gene as predictor of response in a cocaine vaccine clinical trial. <i>Neuroscience Letters</i> , 2013, 541, 29-33.	2.1	30
88	Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study. <i>Journal of Psychiatric Research</i> , 2013, 47, 1049-1053.	3.1	20
89	Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population. <i>Drug and Alcohol Dependence</i> , 2013, 130, 94-100.	3.2	36
90	Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. <i>Drug and Alcohol Dependence</i> , 2013, 132, 674-680.	3.2	34

#	ARTICLE	IF	CITATIONS
91	Can you vaccinate against substance abuse?. Expert Opinion on Biological Therapy, 2013, 13, 1093-1097.	3.1	26
92	Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophrenia Research, 2013, 143, 301-306.	2.0	39
93	Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Research, 2012, 198, 329-331.	3.3	21
94	Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 34-38.	4.8	48
95	Gender differences in cognitive function of patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 358-363.	4.8	111
96	Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophrenia Research, 2012, 141, 48-53.	2.0	12
97	Cigarette Smoking in Male Patients with Chronic Schizophrenia in a Chinese Population: Prevalence and Relationship to Clinical Phenotypes. PLoS ONE, 2012, 7, e30937.	2.5	45
98	Cigarette Smoking and Cognitive Function in Chinese Male Schizophrenia: A Case-Control study. PLoS ONE, 2012, 7, e36563.	2.5	41
99	Association of Catecholâ€œmethyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 370-375.	1.7	26
100	Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology, 2012, 222, 277-284.	3.1	134
101	Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics, 2012, 131, 1187-1195.	3.8	103
102	The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. Journal of Psychiatric Research, 2012, 46, 733-737.	3.1	12
103	BDNF Val66Met Variant and Smoking in a Chinese Population. PLoS ONE, 2012, 7, e53295.	2.5	18
104	Smoking and tardive dyskinesia in male patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1765-1769.	4.8	23
105	Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Research, 2011, 186, 451-453.	3.3	19
106	Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology, 2011, 216, 9-16.	3.1	39
107	Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology, 2010, 212, 301-307.	3.1	44
108	Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: Association with dyskinesic movements. Journal of Psychiatric Research, 2010, 44, 429-433.	3.1	17



#	ARTICLE	IF	CITATIONS
109	The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population. <i>Schizophrenia Research</i> , 2010, 120, 240-242.	2.0	15
110	Association of the manganese superoxide dismutase gene Ala <sup>9</sup> Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 692-696.	4.8	19
111	Cocaine Vaccine for the Treatment of Cocaine Dependence in Methadone-Maintained Patients. <i>Archives of General Psychiatry</i> , 2009, 66, 1116.	12.3	241
112	Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population. <i>Brain Research</i> , 2009, 1287, 67-73.	2.2	23
113	Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. <i>Psychopharmacology</i> , 2009, 204, 177-184.	3.1	77
114	Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. <i>Psychopharmacology</i> , 2009, 205, 647-654.	3.1	30
115	Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. <i>Psychopharmacology</i> , 2009, 207, 375-380.	3.1	134
116	Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1508-1512.	4.8	146
117	Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. <i>Neuroscience Letters</i> , 2009, 462, 113-117.	2.1	31
118	The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. <i>Schizophrenia Research</i> , 2009, 113, 151-157.	2.0	73
119	Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. <i>Psychopharmacology</i> , 2008, 201, 383-389.	3.1	30
120	Elevated serum levels of tumor necrosis factor- $\alpha$ in clozapine-associated obesity in chronic schizophrenia. <i>Schizophrenia Research</i> , 2008, 106, 367-368.	2.0	10
121	Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients. <i>Schizophrenia Research</i> , 2008, 106, 369-370.	2.0	10
122	Association between interleukin-6 receptor polymorphism and patients with schizophrenia. <i>Schizophrenia Research</i> , 2008, 102, 346-347.	2.0	28
123	Vaccine Pharmacotherapy for the Treatment of Cocaine Dependence. <i>Biological Psychiatry</i> , 2005, 58, 158-164.	1.3	202
124	Human therapeutic cocaine vaccine: safety and immunogenicity. <i>Vaccine</i> , 2002, 20, 1196-1204.	3.8	174
125	Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. <i>Psychopharmacology</i> , 2001, 155, 327-329.	3.1	15
126	General Approaches to Substance and Polydrug Use Disorders. , 0, , 957-970.		2